Loading…
PharmaZee was warned for misbranding compounded semaglutide and tirzepatide products sold through its website in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made unsubstantiated claims that the products were "clinically proven medications" and equivalent to FDA-approved versions like Ozempic and Wegovy, despite compounded drugs lacking FDA approval. These misleading representations on the website's labeling and promotional content violated sections 502(a) and 502(bb) of the FDCA by implying the compounded products had been FDA-evaluated for safety and effectiveness.